Multi-focal laser surgery: cutting enhancement by hydrodynamic interactions between cavitation bubbles

Transparent biological tissues can be precisely dissected with ultrafast lasers using optical breakdown in the tight focal zone. Typically, tissues are cut by sequential application of pulses, each of which produces a single cavitation bubble. We investigate the hydrodynamic interactions between simultaneous cavitation bubbles originating from multiple laser foci. Simultaneous expansion and collapse of cavitation bubbles can enhance the cutting efficiency by increasing the resulting deformations in tissue, and the associated rupture zone. An analytical model of the flow induced by the bubbles is presented and experimentally verified. The threshold strain of the material rupture is measured in a model tissue. Using the computational model and the experimental value of the threshold strain one can compute the shape of the rupture zone in tissue resulting from application of multiple bubbles. With the threshold strain of 0.7 two simultaneous bubbles produce a continuous cut when applied at the distance 1.35 times greater than that required in sequential approach. Simultaneous focusing of the laser in multiple spots along the line of intended cut can extend this ratio to 1.7. Counter-propagating jets forming during collapse of two bubbles in materials with low viscosity can further extend the cutting zone - up to a factor of 1.54.Comment: 16 pages, 8 figures. Paper is accepted for publication in Physical Review

2018 Beam-park observations of space debris with the EISCAT radars

Source at https://conference.sdo.esoc.esa.int/proceedings/neosst1/paper/480.Monitoring the evolution of the space debris environment requires regular radar observations of the space debris population. This study presents the results from 24 hours of beam-park observations of space objects conducted simultaneously with the EISCAT Svalbard and Tromsø radars on and between January 4th and 5th, 2018. The measurements are processed with a new matched filter bank analysis program, which doubles the coherent integration time, and hence sensitivity, compared with the previous program. We observe 2077 objects with the Tromsø radar and 2400 objects with the Svalbard radar. The detections are correlated with the NORAD catalog. We find that 68% of the Tromsø and 85% of the Svalbard radar detections are from objects in the NORAD catalog, with most of the catalog object detections being in the side lobes of the radar antenna. The beam-park data are compared with a simulated beam-park experiment for catalog objects. The simulation uses a radar detection model that includes the effects of coherent integration and an antenna beam shape with side lobes. We find that the simulation agrees well with the measurements, indicating that the radar sensor response is accurately modeled. Our results highlight the importance of modeling antenna side lobes when analyzing beam-park measurements. Not taking taking into account side lobe detections can lead to an underestimation of radar cross-sections and an overestimation of population density

Drag and Solar Sail Deorbiting: Re-Entry Time Versus Cumulative Collision Probability

Solar and drag sailing have been proposed as passive end-of-life deorbiting methods, and technological demonstrators are under development. For orbit above 800 km altitude solar radiation pressure can be exploited for increasing the orbit eccentricity until the perigee enters the drag region until final re-entry. The performance of the sailing strategy is determined by four parameters: the required effective area-to-mass ratio to deorbit the spacecraft, which determine the sail size given the satellite’s mass, the time to deorbit and the augmented collision probability caused on and by the sail through its passage in the Low Earth Orbit protected region densely populated by space debris. In this paper we assess the sail dimension with respect to the augmented collision risk depending on the sail area and the deorbiting time

Grb7 SH2 domain structure and interactions with a cyclic peptide inhibitor of cancer cell migration and proliferation

<p>Abstract</p> <p>Background</p> <p>Human growth factor receptor bound protein 7 (Grb7) is an adapter protein that mediates the coupling of tyrosine kinases with their downstream signaling pathways. Grb7 is frequently overexpressed in invasive and metastatic human cancers and is implicated in cancer progression via its interaction with the ErbB2 receptor and focal adhesion kinase (FAK) that play critical roles in cell proliferation and migration. It is thus a prime target for the development of novel anti-cancer therapies. Recently, an inhibitory peptide (G7-18NATE) has been developed which binds specifically to the Grb7 SH2 domain and is able to attenuate cancer cell proliferation and migration in various cancer cell lines.</p> <p>Results</p> <p>As a first step towards understanding how Grb7 may be inhibited by G7-18NATE, we solved the crystal structure of the Grb7 SH2 domain to 2.1 Å resolution. We describe the details of the peptide binding site underlying target specificity, as well as the dimer interface of Grb 7 SH2. Dimer formation of Grb7 was determined to be in the μM range using analytical ultracentrifugation for both full-length Grb7 and the SH2 domain alone, suggesting the SH2 domain forms the basis of a physiological dimer. ITC measurements of the interaction of the G7-18NATE peptide with the Grb7 SH2 domain revealed that it binds with a binding affinity of K_d= ~35.7 μM and NMR spectroscopy titration experiments revealed that peptide binding causes perturbations to both the ligand binding surface of the Grb7 SH2 domain as well as to the dimer interface, suggesting that dimerisation of Grb7 is impacted on by peptide binding.</p> <p>Conclusion</p> <p>Together the data allow us to propose a model of the Grb7 SH2 domain/G7-18NATE interaction and to rationalize the basis for the observed binding specificity and affinity. We propose that the current study will assist with the development of second generation Grb7 SH2 domain inhibitors, potentially leading to novel inhibitors of cancer cell migration and invasion.</p

Mesenchymal stromal cell treatment of donor kidneys during ex-vivo normothermic machine perfusion:A porcine renal autotransplantation study

Normothermic machine perfusion (NMP) of injured kidneys offers the opportunity for interventions to metabolically active organs prior to transplantation. Mesenchymal stromal cells (MSCs) can exert regenerative and anti-inflammatory effects in ischaemia-reperfusion injury. The aims of this study were to evaluate the safety and feasibility of MSC treatment of kidneys during NMP using a porcine auto-transplantation model, and examine potential MSC treatment-associated kidney improvements up to 14 days post transplantation. After 75 minutes of kidney warm ischaemia, four experimental groups of n=7 underwent 14 hours of oxygenated hypothermic machine perfusion. In three groups this was followed by 240 minutes of NMP with infusion of vehicle, ten million porcine or ten million human adipose derived MSCs. All kidneys were auto-transplanted after contralateral nephrectomy. MSC treatment did not affect perfusion haemodynamics during NMP or cause adverse effects at reperfusion, with 100% animal survival. MSCs did not affect plasma creatinine, glomerular filtration rate, neutrophil gelatinase-associated lipocalin concentrations or kidney damage assessed by histology during the 14 days, and MSCs retention was demonstrated in renal cortex. Infusing MSCs during ex vivo NMP of porcine kidneys was safe and feasible. Within the short post- transplant

Results of an open label feasibility study of sodium valproate in people with McArdle disease

McArdle disease results from a lack of muscle glycogen phosphorylase in skeletal muscle tissue. Regenerating skeletal muscle fibres can express the brain glycogen phosphorylase isoenzyme. Stimulating expression of this enzyme could be a therapeutic strategy. Animal model studies indicate that sodium valproate (VPA) can increase expression of phosphorylase in skeletal muscle affected with McArdle disease. This study was designed to assess whether VPA can modify expression of brain phosphorylase isoenzyme in people with McArdle disease. This phase II, open label, feasibility pilot study to assess efficacy of six months treatment with VPA (20 mg/kg/day) included 16 people with McArdle disease. Primary outcome assessed changes in VO2peak during an incremental cycle test. Secondary outcomes included: phosphorylase enzyme expression in post-treatment muscle biopsy, total distance walked in 12 min, plasma lactate change (forearm exercise test) and quality of life (SF36). Safety parameters. 14 participants completed the trial, VPA treatment was well tolerated; weight gain was the most frequently reported drug-related adverse event. There was no clinically meaningful change in any of the primary or secondary outcome measures including: VO2peak, 12 min walk test and muscle biopsy to look for a change in the number of phosphorylase positive fibres between baseline and 6 months of treatment. Although this was a small open label feasibility study, it suggests that a larger randomised controlled study of VPA, may not be worthwhile